NYRADA INC. - Announcements

7.41%

29.0¢

Market Cap $69.25M

Healthcare Biotechnology

Nyrada Inc is an Australia-based drug development company. The Company focuses on... Nyrada Inc is an Australia-based drug development company. The Company focuses on development of small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. Its drug development programs include a proprotein convertase subtilisin/kexin type nine (PCSK9) inhibitor for the treatment of high blood low-density lipoprotein (LDL)-cholesterol levels in patients poorly responsive to or unable to take statin drugs. It develops a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury. The Company also develops a drug to treat pain associated with peripheral nerve damage and autoimmune diseases such as psoriasis.More

Recce Pharmaceuticals (ASX:RCE) eyes US Defence grants with early data for R327 on burn wounds

Announcements

Filter Results

All Price Sensitive Only

NYR	Cleansing Statement		22/08/25	220.62KB	Share
NYR	Application for quotation of securities - NYR		22/08/25	15.72KB	Share
NYR	Notification regarding unquoted securities - NYR		22/08/25	17.67KB	Share
NYR	Full Year Results FY2025		22/08/25	251.86KB	Share
NYR	Annual Report for year ended 30 June 2025		22/08/25	2.05MB	Share
NYR	Appendix 4G and Corporate Governance Statement		22/08/25	813.63KB	Share
NYR	Preliminary Final Report	PRICE SENSITIVE	22/08/25	439.53KB	Share
NYR	Securities Trading Policy		22/08/25	357.85KB	Share
NYR	Notification regarding unquoted securities - NYR		20/08/25	26.06KB	Share
NYR	Response to ASX Cleansing Notice Timing Letter		14/08/25	523.83KB	Share
NYR	Cleansing Statement		13/08/25	242.15KB	Share
NYR	Application for quotation of securities - NYR		13/08/25	15.51KB	Share
NYR	NYR Appoints Consultant Cardiologist for Phase IIa Trial		13/08/25	211.39KB	Share
NYR	Cleansing Statement		11/08/25	227.19KB	Share
NYR	Application for quotation of securities - NYR		11/08/25	15.78KB	Share
NYR	Positive Final Review of Nyrada Phase I Clinical Trial	PRICE SENSITIVE	06/08/25	254.44KB	Share
NYR	BioShares Biotech Summit Presentation		06/08/25	1.47MB	Share
NYR	Change in substantial holding - M Azzi		05/08/25	415.48KB	Share
NYR	Cleansing Statement		04/08/25	234.91KB	Share
NYR	Application for quotation of securities - NYR		04/08/25	15.68KB	Share
NYR	Application for quotation of securities - NYR		04/08/25	15.93KB	Share
NYR	Proposed issue of securities - NYR		04/08/25	15.74KB	Share
NYR	Proposed issue of securities - NYR		04/08/25	21.07KB	Share
NYR	Nyrada Successfully Raises $8.25 Million via Placement	PRICE SENSITIVE	04/08/25	309.41KB	Share
NYR	Change in substantial holding - M Azzi		31/07/25	226.55KB	Share
NYR	Trading Halt	PRICE SENSITIVE	31/07/25	336.99KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	31/07/25	451.07KB	Share
NYR	Top 20 CDI Holder List		31/07/25	235.3KB	Share
NYR	NYR Advances Xolatryp Phase IIa Trial in Cardioprotection	PRICE SENSITIVE	23/07/25	287.44KB	Share
NYR	Final Phase I Clinical Trial Patients Dosed and Discharged	PRICE SENSITIVE	21/07/25	284.22KB	Share
NYR	Final Nyrada Phase I Clinical Trial Cohort to Commence	PRICE SENSITIVE	14/07/25	282.83KB	Share
NYR	Notice of Change of Interests of Substantial Holder - M Azzi		04/07/25	213.39KB	Share
NYR	Proposed issue of securities - NYR		30/06/25	15.35KB	Share
NYR	Notice of Change of Interests of Substantial Holder - M Azzi		25/06/25	212.04KB	Share
NYR	Phase I Clinical Trial Dosing Update No 4	PRICE SENSITIVE	16/06/25	267.76KB	Share
NYR	Nyrada Investor Conference Call		16/06/25	267.38KB	Share
NYR	Non-Deal Investor Presentation		16/06/25	2.32MB	Share
NYR	Change of Director's Interest Notice - RW		13/06/25	6.13KB	Share
NYR	Change of Director's Interest Notice - MF		13/06/25	6.13KB	Share
NYR	Change of Director's Interest Notice - CC		13/06/25	6.2KB	Share
NYR	Change of Director's Interest Notice - JM		13/06/25	6.13KB	Share
NYR	Notification of cessation of securities - NYR		13/06/25	14.48KB	Share
NYR	Notice of Change of Interests of Substantial Holder - M Azzi		12/06/25	226.45KB	Share
NYR	Notice of Change of Interests of Substantial Holder - M Azzi		05/06/25	213.01KB	Share
NYR	Phase I Clinical Trial Protocol Amendment	PRICE SENSITIVE	04/06/25	260.08KB	Share
NYR	Notice of Change of Interests of Substantial Holder - M Azzi		03/06/25	222.36KB	Share
NYR	Notice of Change of Interests of Substantial Holder - M Azzi		28/05/25	208.64KB	Share
NYR	Notice of Change of Interests of Substantial Holder - M Azzi		26/05/25	222.29KB	Share
NYR	Lead Drug Candidate Renamed to Xolatryp		23/05/25	255.2KB	Share
NYR	Notice of Change of Interests of Substantial Holder - M Azzi		21/05/25	208.56KB	Share
NYR	Phase I Clinical Trial Dosing Update No 3	PRICE SENSITIVE	21/05/25	245.1KB	Share
NYR	Change of Director's Interest Notice - JM		21/05/25	7.24KB	Share
NYR	Change of Director's Interest Notice - MF		21/05/25	7.24KB	Share
NYR	Change of Director's Interest Notice - RW		21/05/25	7.11KB	Share
NYR	Change of Director's Interest Notice - CC		21/05/25	7.1KB	Share
NYR	Notice of Ceasing to be a Substantial Holder - NOX		21/05/25	231.61KB	Share
NYR	Notice of Change of Interests of Substantial Holder from NOX		20/05/25	212.7KB	Share
NYR	Corporate Update		20/05/25	217.56KB	Share
NYR	NOX: New funds from Nyrada share sales	PRICE SENSITIVE	20/05/25	193.35KB	Share
NYR	Notification regarding unquoted securities - NYR		15/05/25	25.2KB	Share
NYR	Cleansing Statement		15/05/25	191.89KB	Share
NYR	Application for quotation of securities - NYR		15/05/25	15.64KB	Share
NYR	NYR-BI03 Extends Cardioprotection to Arrhythmia Control	PRICE SENSITIVE	08/05/25	332.15KB	Share
NYR	Phase I Clinical Trial Dosing Update No 2	PRICE SENSITIVE	02/05/25	224.62KB	Share
NYR	Results of Meeting		17/04/25	251.46KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	15/04/25	487.88KB	Share
NYR	Notice of Initial Substantial Holder - M Azzi		09/04/25	207.37KB	Share
NYR	Phase I Clinical Trial Dosing Update No 1	PRICE SENSITIVE	09/04/25	301.12KB	Share
NYR	Significant Neuroprotection in Traumatic Brain Injury Study	PRICE SENSITIVE	07/04/25	340.77KB	Share
NYR	First Cohort Dosed in Nyradas Phase I Clinical Trial	PRICE SENSITIVE	31/03/25	229.29KB	Share
NYR	Nyrada Commences Phase I Clinical Trial Recruitment		17/03/25	228.94KB	Share
NYR	2025 EGM Letter to Shareholders, Notice of Meeting and Proxy		12/03/25	1.57MB	Share
NYR	Nyrada Half Year Results FY2025		18/02/25	313.46KB	Share
NYR	Appendix 4D and Half Year Report to 31 December 2024	PRICE SENSITIVE	18/02/25	458.23KB	Share
NYR	Nyrada to Commence Phase Ia Clinical Trial	PRICE SENSITIVE	07/02/25	233.68KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	23/01/25	461.69KB	Share
NYR	Change of Director's Interest Notice - JM		23/01/25	5.09KB	Share
NYR	Change of Director's Interest Notice - MF		22/01/25	5.06KB	Share
NYR	Change of Director's Interest Notice - RW		22/01/25	5.89KB	Share
NYR	Change of Director's Interest Notice - CC		22/01/25	5.17KB	Share
NYR	Change of Director's Interest Notice - ID		21/01/25	4.89KB	Share
NYR	Notification of cessation of securities - NYR		21/01/25	16.02KB	Share
NYR	NYR-BI03 Phase Ia Clinical Trial Update 2		31/12/24	238.78KB	Share
NYR	Nyrada Receives A$1.235M R&D Tax Incentive Rebate		24/12/24	202.71KB	Share
NYR	Upcoming Expiry of Unlisted Warrants		23/12/24	234.34KB	Share
NYR	NYR-BI03 Phase Ia Clinical Trial Update - Correction		17/12/24	276.17KB	Share
NYR	NYR-BI03 Phase Ia Clinical Trial Update		16/12/24	214.33KB	Share
NYR	Application for quotation of securities - NYR		09/12/24	15.47KB	Share
NYR	Securities Purchase Plan Closure		06/12/24	193.93KB	Share
NYR	Investor Presentation		25/11/24	1.75MB	Share
NYR	Nyrada Investor Conference Call Reminder		25/11/24	266.65KB	Share
NYR	Change of Director's Interest Notice - GM		14/11/24	4.88KB	Share
NYR	Notification regarding unquoted securities - NYR		14/11/24	16.43KB	Share
NYR	Nyrada Annual General Meeting Results		12/11/24	213.91KB	Share
NYR	CEO AGM Presentation		12/11/24	1.04MB	Share
NYR	Nyrada AGM 2024 Chair Address		12/11/24	249KB	Share
NYR	Change of Registered Office and Principal Place of Business		11/11/24	233.86KB	Share
NYR	Nyrada Investor Conference Call		08/11/24	266.94KB	Share
NYR	Notice of Change of Interests of a Sub Securityholder		05/11/24	234.94KB	Share
NYR	Notice of Ceasing to be a Substantial Securityholder		05/11/24	212.41KB	Share

NYR Cleansing Statement
22/08/25		220.62KB	Share
NYR Application for quotation of securities - NYR
22/08/25		15.72KB	Share
NYR Notification regarding unquoted securities - NYR
22/08/25		17.67KB	Share
NYR Full Year Results FY2025
22/08/25		251.86KB	Share
NYR Annual Report for year ended 30 June 2025
22/08/25		2.05MB	Share
NYR Appendix 4G and Corporate Governance Statement
22/08/25		813.63KB	Share
NYR Preliminary Final Report
22/08/25	PRICE SENSITIVE	439.53KB	Share
NYR Securities Trading Policy
22/08/25		357.85KB	Share
NYR Notification regarding unquoted securities - NYR
20/08/25		26.06KB	Share
NYR Response to ASX Cleansing Notice Timing Letter
14/08/25		523.83KB	Share
NYR Cleansing Statement
13/08/25		242.15KB	Share
NYR Application for quotation of securities - NYR
13/08/25		15.51KB	Share
NYR NYR Appoints Consultant Cardiologist for Phase IIa Trial
13/08/25		211.39KB	Share
NYR Cleansing Statement
11/08/25		227.19KB	Share
NYR Application for quotation of securities - NYR
11/08/25		15.78KB	Share
NYR Positive Final Review of Nyrada Phase I Clinical Trial
06/08/25	PRICE SENSITIVE	254.44KB	Share
NYR BioShares Biotech Summit Presentation
06/08/25		1.47MB	Share
NYR Change in substantial holding - M Azzi
05/08/25		415.48KB	Share
NYR Cleansing Statement
04/08/25		234.91KB	Share
NYR Application for quotation of securities - NYR
04/08/25		15.68KB	Share
NYR Application for quotation of securities - NYR
04/08/25		15.93KB	Share
NYR Proposed issue of securities - NYR
04/08/25		15.74KB	Share
NYR Proposed issue of securities - NYR
04/08/25		21.07KB	Share
NYR Nyrada Successfully Raises $8.25 Million via Placement
04/08/25	PRICE SENSITIVE	309.41KB	Share
NYR Change in substantial holding - M Azzi
31/07/25		226.55KB	Share
NYR Trading Halt
31/07/25	PRICE SENSITIVE	336.99KB	Share
NYR Quarterly Activities Report and Appendix 4C
31/07/25	PRICE SENSITIVE	451.07KB	Share
NYR Top 20 CDI Holder List
31/07/25		235.3KB	Share
NYR NYR Advances Xolatryp Phase IIa Trial in Cardioprotection
23/07/25	PRICE SENSITIVE	287.44KB	Share
NYR Final Phase I Clinical Trial Patients Dosed and Discharged
21/07/25	PRICE SENSITIVE	284.22KB	Share
NYR Final Nyrada Phase I Clinical Trial Cohort to Commence
14/07/25	PRICE SENSITIVE	282.83KB	Share
NYR Notice of Change of Interests of Substantial Holder - M Azzi
04/07/25		213.39KB	Share
NYR Proposed issue of securities - NYR
30/06/25		15.35KB	Share
NYR Notice of Change of Interests of Substantial Holder - M Azzi
25/06/25		212.04KB	Share
NYR Phase I Clinical Trial Dosing Update No 4
16/06/25	PRICE SENSITIVE	267.76KB	Share
NYR Nyrada Investor Conference Call
16/06/25		267.38KB	Share
NYR Non-Deal Investor Presentation
16/06/25		2.32MB	Share
NYR Change of Director's Interest Notice - RW
13/06/25		6.13KB	Share
NYR Change of Director's Interest Notice - MF
13/06/25		6.13KB	Share
NYR Change of Director's Interest Notice - CC
13/06/25		6.2KB	Share
NYR Change of Director's Interest Notice - JM
13/06/25		6.13KB	Share
NYR Notification of cessation of securities - NYR
13/06/25		14.48KB	Share
NYR Notice of Change of Interests of Substantial Holder - M Azzi
12/06/25		226.45KB	Share
NYR Notice of Change of Interests of Substantial Holder - M Azzi
05/06/25		213.01KB	Share
NYR Phase I Clinical Trial Protocol Amendment
04/06/25	PRICE SENSITIVE	260.08KB	Share
NYR Notice of Change of Interests of Substantial Holder - M Azzi
03/06/25		222.36KB	Share
NYR Notice of Change of Interests of Substantial Holder - M Azzi
28/05/25		208.64KB	Share
NYR Notice of Change of Interests of Substantial Holder - M Azzi
26/05/25		222.29KB	Share
NYR Lead Drug Candidate Renamed to Xolatryp
23/05/25		255.2KB	Share
NYR Notice of Change of Interests of Substantial Holder - M Azzi
21/05/25		208.56KB	Share
NYR Phase I Clinical Trial Dosing Update No 3
21/05/25	PRICE SENSITIVE	245.1KB	Share
NYR Change of Director's Interest Notice - JM
21/05/25		7.24KB	Share
NYR Change of Director's Interest Notice - MF
21/05/25		7.24KB	Share
NYR Change of Director's Interest Notice - RW
21/05/25		7.11KB	Share
NYR Change of Director's Interest Notice - CC
21/05/25		7.1KB	Share
NYR Notice of Ceasing to be a Substantial Holder - NOX
21/05/25		231.61KB	Share
NYR Notice of Change of Interests of Substantial Holder from NOX
20/05/25		212.7KB	Share
NYR Corporate Update
20/05/25		217.56KB	Share
NYR NOX: New funds from Nyrada share sales
20/05/25	PRICE SENSITIVE	193.35KB	Share
NYR Notification regarding unquoted securities - NYR
15/05/25		25.2KB	Share
NYR Cleansing Statement
15/05/25		191.89KB	Share
NYR Application for quotation of securities - NYR
15/05/25		15.64KB	Share
NYR NYR-BI03 Extends Cardioprotection to Arrhythmia Control
08/05/25	PRICE SENSITIVE	332.15KB	Share
NYR Phase I Clinical Trial Dosing Update No 2
02/05/25	PRICE SENSITIVE	224.62KB	Share
NYR Results of Meeting
17/04/25		251.46KB	Share
NYR Quarterly Activities Report and Appendix 4C
15/04/25	PRICE SENSITIVE	487.88KB	Share
NYR Notice of Initial Substantial Holder - M Azzi
09/04/25		207.37KB	Share
NYR Phase I Clinical Trial Dosing Update No 1
09/04/25	PRICE SENSITIVE	301.12KB	Share
NYR Significant Neuroprotection in Traumatic Brain Injury Study
07/04/25	PRICE SENSITIVE	340.77KB	Share
NYR First Cohort Dosed in Nyradas Phase I Clinical Trial
31/03/25	PRICE SENSITIVE	229.29KB	Share
NYR Nyrada Commences Phase I Clinical Trial Recruitment
17/03/25		228.94KB	Share
NYR 2025 EGM Letter to Shareholders, Notice of Meeting and Proxy
12/03/25		1.57MB	Share
NYR Nyrada Half Year Results FY2025
18/02/25		313.46KB	Share
NYR Appendix 4D and Half Year Report to 31 December 2024
18/02/25	PRICE SENSITIVE	458.23KB	Share
NYR Nyrada to Commence Phase Ia Clinical Trial
07/02/25	PRICE SENSITIVE	233.68KB	Share
NYR Quarterly Activities Report and Appendix 4C
23/01/25	PRICE SENSITIVE	461.69KB	Share
NYR Change of Director's Interest Notice - JM
23/01/25		5.09KB	Share
NYR Change of Director's Interest Notice - MF
22/01/25		5.06KB	Share
NYR Change of Director's Interest Notice - RW
22/01/25		5.89KB	Share
NYR Change of Director's Interest Notice - CC
22/01/25		5.17KB	Share
NYR Change of Director's Interest Notice - ID
21/01/25		4.89KB	Share
NYR Notification of cessation of securities - NYR
21/01/25		16.02KB	Share
NYR NYR-BI03 Phase Ia Clinical Trial Update 2
31/12/24		238.78KB	Share
NYR Nyrada Receives A$1.235M R&D Tax Incentive Rebate
24/12/24		202.71KB	Share
NYR Upcoming Expiry of Unlisted Warrants
23/12/24		234.34KB	Share
NYR NYR-BI03 Phase Ia Clinical Trial Update - Correction
17/12/24		276.17KB	Share
NYR NYR-BI03 Phase Ia Clinical Trial Update
16/12/24		214.33KB	Share
NYR Application for quotation of securities - NYR
09/12/24		15.47KB	Share
NYR Securities Purchase Plan Closure
06/12/24		193.93KB	Share
NYR Investor Presentation
25/11/24		1.75MB	Share
NYR Nyrada Investor Conference Call Reminder
25/11/24		266.65KB	Share
NYR Change of Director's Interest Notice - GM
14/11/24		4.88KB	Share
NYR Notification regarding unquoted securities - NYR
14/11/24		16.43KB	Share
NYR Nyrada Annual General Meeting Results
12/11/24		213.91KB	Share
NYR CEO AGM Presentation
12/11/24		1.04MB	Share
NYR Nyrada AGM 2024 Chair Address
12/11/24		249KB	Share
NYR Change of Registered Office and Principal Place of Business
11/11/24		233.86KB	Share
NYR Nyrada Investor Conference Call
08/11/24		266.94KB	Share
NYR Notice of Change of Interests of a Sub Securityholder
05/11/24		234.94KB	Share
NYR Notice of Ceasing to be a Substantial Securityholder
05/11/24		212.41KB	Share

REFRESH

1 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 29.0¢		Change 0.020(7.41%)		Mkt cap ! $69.25M

Open	High	Low	Value	Volume
27.0¢	29.0¢	27.0¢	$125.1K	445.1K

Buyers (Bids)

No.	Vol.	Price($)
2	19172	29.0¢

Sellers (Offers)

Price($)	Vol.	No.
29.5¢	7200	1

View Market Depth

No.	Vol.	Price($)
1	2000	0.290
2	15000	0.285
2	32000	0.280
1	36363	0.275
1	67735	0.270

Price($)	Vol.	No.
0.295	7200	1
0.300	20000	1
0.310	15075	2
0.320	178150	4
0.340	69332	1

Last trade - 16.10pm 05/09/2025 (20 minute delay)

NYR (ASX) Chart

NYRADA INC. - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories